Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 3/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27468546 | 0.91 | HCAR2 (0.40) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL3575824 | 0.87 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL1070 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| Methane SCHEMBL28911261 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL27596057 | 0.84 | KDM4C (0.43) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL3830795 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL4744537 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL6632512 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL27468545 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL5416943 | 0.76 | MAPT (0.36) | SMN1; SMN2ALDH1A1MAPTGAAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PFIZER INC | 2006-12-28 | — | — | US | disclosed |
| CN-1281588-C | Novel intermediate for prepn. of pyrazolopyrimidinones | PFIZER (US) | 2006-10-25 | — | — | CN | disclosed |
| CN-1229349-C | Pyridine-3-carboxylic acid derivative | PFIZER (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6916927-B2 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC. | 2005-07-12 | — | — | US | disclosed |
| CN-1626516-A | Novel intermediate for prepn. of pyrazolopyrimidinones | PFIZER (US) | 2005-06-15 | — | — | CN | disclosed |
| CN-1188415-C | Pyrazolopyrimidinones inhibiting type 5 cyclic guanosine 3',5' -monophosphate phosphodiesterase (cG MP PDE5) for the treatment of sexual dysfunction | PFIZER LTD (US) | 2005-02-09 | — | — | CN | disclosed |
| EP-1305314-B1 | CRYSTALLINE THERAPEUTIC AGENT | PFIZER LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-0977756-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998049166-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
| US-5719283-A | INHIBITORS OF PHOSPHODIESTERASES; CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1998-02-17 | — | — | US | disclosed |
| CN-1028758-C | Pyrazolopyrimidinone antianginal agents | PFIZER (US) | 1995-06-07 | — | — | CN | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
| CN-1057464-A | Pyrazolopyrimidinoneantianginal antianginal agents | PFIZER (US) | 1992-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1628/4885ALDH1A1 758/4885MAPT 3997/4885 |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1628/4885ALDH1A1 758/4885MAPT 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.